

Piotr Raubo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9636543/publications.pdf>

Version: 2024-02-01

12
papers

360
citations

1040056

9
h-index

1281871

11
g-index

12
all docs

12
docs citations

12
times ranked

687
citing authors

#	ARTICLE	IF	CITATIONS
1	Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6. ACS Chemical Biology, 2018, 13, 3131-3141.	3.4	110
2	Discovery of Pyrazolo[1,5- <i>a</i>]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic Inhibitors. Journal of Medicinal Chemistry, 2017, 60, 4386-4402.	6.4	57
3	The acute glucose lowering effect of specific GPR120 activation in mice is mainly driven by glucagon-like peptide 1. PLoS ONE, 2017, 12, e0189060.	2.5	37
4	Discovery of AZD4625, a Covalent Allosteric Inhibitor of the Mutant GTPase KRAS ^{G12C} . Journal of Medicinal Chemistry, 2022, 65, 6940-6952.	6.4	29
5	Potent, selective small molecule inhibitors of type III phosphatidylinositol-4-kinase $\hat{1}\pm$ - but not $\hat{1}^2$ -inhibit the phosphatidylinositol signaling cascade and cancer cell proliferation. Chemical Communications, 2014, 50, 5388-5390.	4.1	28
6	Indazole-6-phenylcyclopropylcarboxylic Acids as Selective GPR120 Agonists with in Vivo Efficacy. Journal of Medicinal Chemistry, 2017, 60, 3187-3197.	6.4	28
7	Free Ligand 1D NMR Conformational Signatures To Enhance Structure Based Drug Design of a Mcl-1 Inhibitor (AZD5991) and Other Synthetic Macrocycles. Journal of Medicinal Chemistry, 2019, 62, 9418-9437.	6.4	25
8	Solid-Phase Synthesis of Oxetane Modified Peptides. Organic Letters, 2017, 19, 3303-3306.	4.6	23
9	Discovery of potent, selective small molecule inhibitors of $\hat{1}\pm$ -subtype of type III phosphatidylinositol-4-kinase (PI4KIII $\hat{1}\pm$). Bioorganic and Medicinal Chemistry Letters, 2015, 25, 3189-3193.	2.2	11
10	The discovery and evaluation of 3-amino-2(1H)-pyrazinones as a novel series of selective p38 $\hat{1}\pm$ MAP kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127412.	2.2	6
11	Development of oxetane modified building blocks for peptide synthesis. Organic and Biomolecular Chemistry, 2020, 18, 5400-5405.	2.8	6
12	Diversity-Orientated Synthesis of Macrocyclic Heterocycles Using Double SNAr Approach.. Organic and Biomolecular Chemistry, 2021, 19, 6274-6290.	2.8	0